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Abstract
Discovery of new viruses has been boosted by novel deep sequencing technologies. Currently, many viruses can be
identified by sequencing without knowledge of the pathogenicity of the virus. However, attributing the presence of a virus
in patient material to a disease in the patient can be a challenge. One approach to meet this challenge is identification of
viral sequences based on enrichment by autologous patient antibody capture. This method facilitates identification of
viruses that have provoked an immune response within the patient and may increase the sensitivity of the current virus
discovery techniques. To demonstrate the utility of this method, virus discovery deep sequencing (VIDISCA-454) was
performed on clinical samples from 19 patients: 13 with a known respiratory viral infection and 6 with a known
gastrointestinal viral infection. Patient sera was collected from one to several months after the acute infection phase. Input
and antibody capture material was sequenced and enrichment was assessed. In 18 of the 19 patients, viral reads from
immunogenic viruses were enriched by antibody capture (ranging between 1.5x to 343x in respiratory material, and 1.4x to
53x in stool). Enriched reads were also determined in an identity independent manner by using a novel algorithm
Xcompare. In 16 of the 19 patients, 21% to 100% of the enriched reads were derived from infecting viruses. In conclusion,
the technique provides a novel approach to specifically identify immunogenic viral sequences among the bulk of sequences
which are usually encountered during virus discovery metagenomics.
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Introduction
Virus infections are a continuous threat to the human
population; e.g. HIV, hepatitis viruses, and influenza viruses
constitute a large proportion of morbidity and mortality each year.
Apart from infection with well-described viruses, outbreaks with
previously undescribed viruses occur regularly (e.g. SARS-CoV,
MERS-CoV) [1–4]. Furthermore, respiratory tract infections and
diarrhoea in young children or immunocompromised persons
often test negative for known viruses, and could very well be
caused by yet unknown pathogens.
Discovery of new viruses in the last decade has been boosted by
large improvements in sequencing technology. These methods
form the basis for improved virus discovery processes capable of
generating 10e5–10e7 sequence reads directly from a clinical
sample. A virus discovery method to amplify RNA and DNA virus
sequences directly in patient material (VIDISCA-454) without
prior knowledge of the viral genome sequence has been developed
[5]. The resulting DNA library is then subjected to Roche-454
next generation sequencing and this method has been successfully
used to identify human coronavirus NL63 [6], a novel HIV-1
subtype [7], and 2 novel parvoviruses in bats [8].
One limitation of the current technique is that a substantial
amount of non-viral RNA and DNA derived from the host or from
other agents in the sample can dominate the resulting sequences.
Especially in respiratory samples, ribosomal RNA is massively
present, over 80% of all sequence reads derived from a clinical
sample originate from this material [9]. Sequence reads from fecal
samples can be dominated by bacterial or dietary components. A
method for focusing sequencing on immunogenic viruses was
sought.
Another limitation of the current techniques is that detection of
reads derived from a known virus does not necessarily indicate that
this virus is a pathogen. Recently, many new viruses have been
identified in human samples without clear association with disease,
necessitating further detailed investigations to determine the
pathogenicity of the virus [10–13].
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To facilitate the detection of immunogenic viruses and to reduce
the detection of non disease-related viruses (bacteriophages and
plant viruses) and host cellular RNA, a technique was developed
that uses convalescent serum of the patient to concentrate viruses
that have elicited and immune response prior to sequencing.
Comparing the sequences derived from input and antibody
captured material identifies immunogenic agents and can provide
an important first step in identifying a disease-related virus.
Methods
Samples
Respiratory samples were collected during the GRACE study.
Flocked nasopharyngeal swabs (Copan) were collected in universal
transport medium (UTM). In addition, a single nasopharyngeal
specimen was obtained at the Academic Medical Center from a
patient with an upper respiratory tract infection.
Fecal samples were selected from a sample bank from 196 HIV-
1-infected patients with and without diarrhea, aged above 18 who
visited the out-patients clinic at the Academic Medical Center in
the years 1994–1995. Fecal samples were suspended in broth (1:3
dilution, Oxoid nutrient broth no.2, pH 7.5).
Ethical approval
Ethics review committees in each country approved the study,
Cardiff and Southampton (United Kingdom): Southampton &
South West Hampshire Research Ethics Committee A; Utrecht
(Netherlands) Medisch Ethische Toetsingscommissie Universitair
Medisch Centrum Utrecht; Barcelona (Spain) Comite` e`tic
d’investigacio´ clı´nica Hospital Clı´nic de Barcelona; Mataro
(Spain): Comite` d’E`tica d’Investigacio´ Clı´nica (CEIC) del Consorci
Sanitari del Maresme; Rotenburg (Germany) Ethik-Kommission
der Medizinischen Fakulta¨t der Georg-August-Universita¨t Go¨ttin-
gen, Antwerpen (Belgium): UZ Antwerpen Comite´ voor Medische
Ethiek; Lodz, Szeczecin, and Bialystok (Poland): Komisja Bioetyki
Uniwersytetu Medycznego W Lodzi; Milano (Italy) IRCCS
Fondazione Ca` Granda Policlinico; Jonkoping (Sweden): Regio-
nala etikpro¨vningsna¨mnden i Linko¨ping; Bratislava (Slovakia):
Etika Komisia Bratislavskeho; Gent (Belgium): Ethisch Comite´
Universitair Ziekenhuis Gent; Nice (France) Comite´ de Protection
des Personnes Sud-Me´diterrane´e II, Hoˆpital Salvator; Jesenice
(Slovenia): Komisija Republike Slovenije za Medicinsko Etiko.
Written informed consent was provided by all study participants.
Collection of fecal material was performed in accordance with
the ethical principles set out in the declaration of Helsinki and
written informed consent has been obtained prior to data
collection. The study was approved by the Amsterdam Medical
Center institutional medical ethics committee.
Antibody capture
Respiratory and fecal samples were centrifuged (10,000 g) and
150 ml of the supernatant was mixed with 50ml Dynabeads protein
A and G (1:1, Invitrogen). After 20 minutes incubation, 10 ml of
autologous convalescent serum of the patient was added to the
mixture (Table 1). After a 20 minutes incubation with continuous
shaking at room temperature, samples were washed six times with
PBS using a magnetic particle concentrator. Universal transport
medium with TURBOTM DNase (2U/ml, Ambion) was added to
the antibody-antigen complex and samples were incubated at
37uC for 30 minutes. The complexes were lysed with Boom-lysis
buffer L6 and the lysate was used as input for Boom extraction
[14], followed by VIDISCA-454 sequencing as described below.
Real time RT-PCR for ribosomal RNA
Real time PCR for ribosomal RNA was performed as described
[5] using primer set 5/6 and the rRNA28S_3674 probe. The
platinum quantitative PCR Supermix-UDG system (Invitrogen)
was used.
VIDISCA and Roche Titanium-454 sequencing
VIDISCA-454 was performed as previously described [5]. In
short, samples were centrifuged for 10 minutes at 10,000 g and the
supernatant was treated with DNase. Subsequently, nucleic acids
were extracted by the Boom extraction method [14]. rRNA-
blocking oligonucleotides were added to prevent amplification of
ribosomal RNA and a reverse transcription reaction with
Superscript II (Invitrogen) was performed using non-ribosomal
random hexamers [15]. Subsequently, second strand DNA
synthesis was performed with 5 U of Klenow fragment (Westburg).
Double-stranded DNA was purified by phenol/chloroform
extraction and ethanol precipitation and digested with Mse I
restriction enzyme (New England Biolabs). Adaptors with different
Multiplex Identifier sequences (MIDs) were ligated to the digested
fragments of the different samples. Next, a PCR with adaptor-
binding primers was performed. After purification (Agencourt
AMPure XP PCR, Beckman Coulter), the purified DNA was
quantified with the Quant-it dsDNA HS Qubit kit (Invitrogen) and
diluted to 107 ng/ml. Samples were pooled and Kapa PCR (Kapa
Biosystems) was performed to determine the quantity of amplifi-
able DNA in each pool. Subsequently, the Bioanalyser (hsDNA
chip, Agencourt) was used to determine the average nucleotide
length of the libraries and the pools were diluted until 106 copies/
ml to be used for a titration (DNA:beads ratio of 0.5:1, 1:1, 2:1 and
4:1) in an emulsion PCR according to the suppliers’ protocol (LIB-
A SV emPCR kit). Sequencing was done on a 2 region GS FLX
Titanium PicoTiterPlate (70675) with GS FLX Titanium XLR 70
Sequencing kit (Roche).
Sequence analysis
Primers, MIDs and ribosomal RNA sequences were trimmed
from the reads. Sequences were compared with all available
sequences in the nonredundant Genbank database [16] via the
BlastN (http://blast.ncbI.nlm.nih.gov/Blast.cgi) tool [17]. The
following Blast settings were used: expect threshold: 1000, Match/
Mismatch Scores: 1.-1, Gap Costs: Existence: 2 Extension: 1. The
blast output was subsequently used to create a taxonomic
Table 1. Collection of serum in month(s) after infection.
Patient ID
DT since
acute phase Patient ID
DT since
acute phase
Patient 1 1 month Patient 11 1 month
Patient 2 1 month Patient 12 1 month
Patient 3 1 month Patient 13 2 months
Patient 4 1 month Patient 14 3 months
Patient 5 1 month Patient 15 5 months
Patient 6 1 month Patient 16 3 months
Patient 7 1 month Patient 17 8 months
Patient 8 1 month Patient 18 4 months
Patient 9 1 month Patient 19 13 months
Patient 10 1 month
doi:10.1371/journal.pone.0078454.t001
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classification of the reads with Megan software version 4.70.4 [18].
The following settings were used: Min Support: 1, Min Score: 80,
and Top Percent 100. The sequences reads are submitted to the
European Nucleotide Archive, accession number PRJEB4561.
Enrichment index
The percentage of viral sequences was calculated by dividing
the number of virus derived reads in the sample by the total
numbers of reads in the same sample. The enrichment index was
calculated by dividing the percentage of viral sequences in the
captured sample by the percentage viral sequences in the input
sample. A value above 1 indicates antibody capture of the virus,
which suggests a immunogenic course of infection.
Determination of enriched sequences
To identify sequences which are enriched by antibody capture,
input and enriched sequences were compared using a Python
algorithm xcompare (source available on request). The algorithm is
comprised of the following steps: the identification of identical or
nearly-identical sequences within the input subset was performed
by creating a custom BLAST database [19] comprising all the
reads derived from the input sample and subsequently performing
a BLAST search within this database towards its own sequences.
Via this method a list of closely related sequences could be created
which were extracted and aligned via MUSCLE 3.8.31 [20,21]
(maximum number of iterations: 1; diagonal optimization enabled)
and both consensus sequences and unique sequences were joined
into a unique fragment library. In turn, this unique fragment
library was converted into a second custom BLAST database,
against which the reads obtained from the enriched sample were
compared. For the BLAST comparison the following settings were
used: E-value threshold 3E-60 for within the input sample library
and 3E-25 for between the enriched and input samples library;
word size: 11; match/mismatch scores 1/-2; gap existence/
extension penalty: 5/2.
The second BLAST analysis yields the percentage of sequence
space occupied by each fragment in the original sample (number
of reads comprising a fragment, divided by the total number of
reads in the input sample library) and the enriched sample
(number of sequences in the enriched sample matching to a
specific fragment, divided by the total number of reads in the
enriched sample library). The ratio between these percentages is
calculated and all fragments with a ratio higher than 1.0 were
extracted and further analyzed.
Results
Serum collected a few weeks to a few months after respiratory or
gastrointestinal infection generally contains a substantial amount
of pathogen-specific immunoglobulin type G (IgGs) with a
proportion of these antibodies binding to virus surface exposed
epitopes [22–24]. These IgGs can be bound to magnetic beads
and used to capture a target virus and to separate it from non-viral
material (e.g. ribosomes) or non-immunogenic viruses (e.g. plant
viruses in stool). After deep sequencing, comparison of reads in the
captured material to reads in the input material should reveal
virus-specific reads via capture by the antibodies. We tested this
strategy in 13 respiratory samples, diagnosed as containing one of
the following viruses: human parainfluenza virus 1, 2 and 4,
human rhinovirus, human metapneumovirus virus, influenza virus
A and B, human respiratory syncytial virus and human
coronavirus 229E, OC43 and NL63. We also tested 6 fecal
samples containing adenovirus, norovirus, enterovirus and sapo-
virus. Autologous convalescent sera collected one to a few months
after infection was available for all samples (see table 1). Plant
viruses and enterobacteriophages - viruses which are frequently
present in feces - were used as negative control. These viruses are
not known to elicit an immune response and are not expected to
be captured by the antibody-bound beads.
Enrichment index
Of the 13 respiratory samples and the 6 fecal samples, a total of
110,752 reads were obtained from the input material and 93,779
reads were obtained from the antibody captured material with a
median read length of 159 nucleotides. For each patient the
enrichment index was determined by calculating the ratio between
the percentage of viral reads in the captured sample versus the
input sample (Table 2).
For all respiratory samples the enrichment index was above 1.0,
indicating that in every sample tested the number of viral reads
increased after capture. The human coronaviruses OC43, NL63
and 229E were detected with an enrichment index of 169, 343 and
23 respectively. In a second NL63 case (patient 6), the virus was
enriched 20-fold. The para-influenza viruses 1, 2 and 4 infections
were detected with an enrichment index of 1.5, 54 and 19
respectively. The enrichment index for the metapneumovirus was
7.2, while it was 1.6 for the respiratory syncytial virus. Human
rhinovirus infection was observed in two different patients and the
enrichment index was 1.9 and 3.1 respectively. Influenza B virus
was detected with an enrichment index of 3.3 and influenza A
virus with an enrichment index of 25.
Fecal samples were analyzed by the same process. Norovirus
infection was observed in two patients and enriched 20-fold and
11-fold. Adenovirus was also detected in a patient with norovirus
infection and no enrichment for adenovirus was scored (0.9).
Enterovirus reads were detected with an enrichment factor of 5.2
in one case but enterovirus reads were not enriched (enrichment
factor of 0.0) in a second case. Viral reads derived from sapovirus
were detected in samples from two patients with an enrichment
factor of 4.9 and 1.4 respectively. Hepatitis B viral reads were
detected in patient 19 with an enrichment factor of 53. As controls,
a plant virus (cucumber mosaic virus) and an enterobacteriophage
were tested. These viruses had an enrichment index of 0.08 and
0.01 respectively, indicating that there presence was reduced in the
captured material.
Consistent with capture working as anticipated, reads derived
from human ribosomal RNA showed a consistent reduction in the
antibody captured fractions with an average decrease of 1,000 fold
(a median decrease of 9.6 Ct values, Figure 1). Greater than 90%
of the reads showing decreased levels were of ribosomal RNA
origin in 11 of the 13 patients. In the two other cases the amount
of ribosomal RNA was low in the input material, but commensal
bacterial reads were massively present and for these patients a
strong decrease (.70%) was observed in the number of bacterial
reads (data not shown).
Identity independent enrichment
The enrichment index shows that viral reads appear more
frequently in the antibody-captured material compared to the
input. This increase can also be used to identify viruses without the
necessity of having sequence similarity to known viruses that can
be probed by Blast to search for identity. Since restriction enzyme
digestion is part of the protocol, identical fragments of the same
size will be generated from identical viruses and this means that
the number of these identical fragments should increase if the
relative load of the virus increases. Xcompare was used to
calculate the frequency distribution between the input and the
captured reads (see Materials and Methods). Reads present in
Virus Discovery Tool Using Autologous Antibodies
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higher quantity in the captured samples compared to the input
samples were selected. Reads originated from archaea, bacteria or
eukaryota were excluded and the remaining reads, (Enriched
Analysis Reads, EAR), were further investigated.
EAR values ranged from 0 to 3019 (Table 3). In respiratory
samples, almost all EAR were derived from viruses. In patients 3–
13, 98–100% of all EAR sequences were of viral origin. Also in
fecal samples, virus reads represent the majority of the EAR. In
patient 14, 30% of the EAR were derived from norovirus and 50%
from adenovirus. In patient 15, all 3019 enriched reads were
derived from norovirus. In patient 16 none of the 42 EAR were
derived from an enterovirus, and also in patient 18 no enterovirus
reads were detected in the EAR as expected since no enterovirus
reads were present in the captured reads. Sapovirus sequences
were detected in the EAR of patient 17 and 18, 21% and 65%
respectively. In patient 19, 62% of the EAR were derived from a
hepatitis B virus. The plant virus and the enterobacteriophage
were not detected in the EAR of patient 15 and 19.
Discussion
A new method is described that facilitates virus identification by
enriching viral material with convalescent autologous patient
antibody capture followed by deep sequencing. For all samples
tested here, an increase in percentage of viral reads was detected
when compared to the input sample. In 9 out of the 21 viruses the
amount of viral reads after capture increase 10-fold or more.
Table 2. Reads of viruses after antibody capture.
Patient ID Virus % viral reads in input % viral reads in capture Enrichment indexa
Patient 1 PIV-1 0.26% 0.38% 1.5
Patient 2 PIV-2 0.07% 3.6% 54
Patient 3 PIV-4 0.78% 15% 19
Patient 4 HRV 42% 77% 1.9
Patient 5 hMPV 1.4% 9.9% 7.2
Patient 6 NL63 1.7% 33% 20
Patient 7 RSV 18% 29% 1.6
Patient 8 Inf B 0.61% 2.0% 3.3
Patient 9 Inf A 3.0% 75% 25
Patient 10 OC43 0.35% 59% 169
Patient 11 NL63 0.14% 48% 343
Patient 12 229E 0.55% 13% 23
Patient 13 HRV 1.4% 4.5% 3.1
Patient 14 Norovirus 0.16% 3.2% 20
Patient 14 Adenovirus 3.9% 3.7% 0.9
Patient 15 Norovirus 8.3% 88% 11
Patient 16 Enterovirus 0.03% 0.18% 5.2
Patient 17 Sapovirus 0.08% 0.40% 4.9
Patient 18 Sapovirus 3.2% 4.5% 1.4
Patient 18 Enterovirus 1.0% 0.00% 0.00
Patient 19: Hepatitis B virus 0.05% 2.50% 53
Patient 15 Cucumber mosaic virusb 0.36% 0.03% 0.08
Patient 19: Caudoviralesb 63% 0.62% 0.01
aThe enrichment index is calculated by dividing the percentage of virus reads in the captured material by the number of virus reads in the input material.
bControl, non pathogenic viruses.
doi:10.1371/journal.pone.0078454.t002
Figure 1. Decrease in ribosomal RNA after antibody capture.
Ribosomal RNA was measured in the input material and the captured
material. On the Y-axis the Ct value of the real time PCR on the cDNA is
shown.
doi:10.1371/journal.pone.0078454.g001
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By using the Xcompare script, enriched reads in the antibody
captured sample could be determined in an identity independent
manner. In 11 out of the 13 patients, between 98% and 100% of
the enriched analysis reads were of mammalian viral origin. In
fecal samples between 21% and 100% viral reads were detected in
the EAR in 4 out of 6 cases. Surprisingly, in two patients with
enterovirus infection, no viral reads were detected in the EAR.
Of note are patient 1 and 2. For both patients viral reads were
increased after capture (table 2), but the EAR contained no PIV-1
or PIV-2 sequences (table 3). This was caused by the comparison
used to determine the EAR; reads which are present in the input
are included in the analysis (see material and methods). Apparently
the low number of viral reads in the captured material were from a
different part of the viral genome than the few reads of the viral
reads in the input. Therefore, it has to be kept in mind that using
this approach during data analysis might diminish the chance to
identify viruses which are hardly present in the input material
when identification is only based on the detection of enriched
sequences. On the other hand, inclusion of the reads which are
only present in one of the two libraries might lead to wrong
interpretations by the presence of experimental artefacts due to
PCR errors and/or chimeric PCR products.
Also enteroviruses were poorly captured. A possible explanation
might be that the bacteria or bacteriophage background in fecal
samples is high which makes it more difficult to enrich a virus with
a relatively low load. Nonetheless, we were able to reduce the
amount of reads originating from bacteriophages and plant viruses
(enrichment index of 0.01 and 0.08), indicating that this method
can efficiently reduce the background in fecal samples. Further-
more, it could be that the immune response to enteroviruses is
poor, especially in immunocompromised patients, which is the
case in our study patients with diarrhoea. These patients were
HIV-1 positive with relatively low CD4 counts (0.18 and
0.05610E9 cells/L in the two patients with enterovirus infection).
On the other hand, it has been published that HIV-1 infected
patients are not hampered in their immune response to
enteroviruses, and chronic shedding is as rare as in the normal
population [25].
Antibody response to a virus infection can vary, depending on
the virus, but also age and immune state of patients. Also,
antibodies subclasses can differ; some viruses elicit a strong IgG
response, while others induce a response dominated by IgA. In our
antibody capture experiment, a combination of protein A and G
coupled beads was used. Both proteins strongly bind to IgGs, but
not or less efficient to IgA. It has been shown that serum
antibodies, for instance against PIV-1 are not neutralizing
efficiently, and that especially secretory IgA plays an important
role in preventing re-infection [26,27]. To address that point,
protein L coupled beads, which are able to capture IgA, were
tested. However, no difference was observed in the amount of
PIV-1 or enterovirus capture (data not shown).
To date many new viruses have been identified [10–13], yet for
a substantial number the link with disease remains to be
established. Especially in stool samples, which contain many
unknown viruses, it is important to determine whether novel
viruses are pathogenic. A pathogenic virus elicits an immune
Table 3. Reads of viruses after antibody capture.
Patient ID Virus Sequences in the enriched analysis-poola % Viral sequences
Patient 1 PIV-1 0 0%
Patient 2 PIV-2 0 0%
Patient 3 PIV-4 99 98%
Patient 4 HRV 1945 100%
Patient 5 hMPV 65 100%
Patient 6 NL63 177 100%
Patient 7 RSV 636 99%
Patient 8 Inf B 13 100%
Patient 9 Inf A 1634 100%
Patient 10 OC43 71 100%
Patient 11 NL63 249 100%
Patient 12 229E 15 100%
Patient 13 Rhino A 124 100%
Patient 14 Norovirus 349 30%
Patient 14 Adenovirus 349 50%
Patient 15 Norovirus 3019 100%
Patient 16 Enterovirus 121 0.00%
Patient 17 Sapovirus 42 21%
Patient 18 Sapovirus 246 65%
Patient 18 Enterovirus 246 0.00%
Patient 19: Hepatitis B virus 21 62%
Patient 15 Cucumber mosaic virusb 3019 0.00%
Patient 19: Caudoviralesb 21 0.00%
aOnly enriched sequences with the potency to be viral are shown, so no known bacterial, human, fungal, etc. or other sequences are included.
bControl, non pathogenic viruses.
doi:10.1371/journal.pone.0078454.t003
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response in the host, whereas bacteriophages and plant viruses,
which are also massively present in stool, do not. The restriction
that the agent has to be recognized by the patients’ antibodies adds
an important selectivity tool to virus discovery when one wants to
focus on pathogenic viruses.
In summary, a new selective approach for virus discovery is
presented that enables detection of viruses that have recently
elicited an immune response resulting in antibody production. The
method appears to be an effective tool for reducing host DNA/
RNA and bystander virus sequences and provides a selection for
viruses that are able to elicit an antibody response, thus agents that
are possibly pathogenic for the host. Moreover, the possibility of
comparing reads obtained after antibody capture with reads
obtained from the input samples is useful for identifying sequences
not yet labelled in Genbank. Further analysis of those sequences
(e.g. via genome walking) will allow the identification and
characterization of viruses which are highly divergent from the
currently known virus families.
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